Century Therapeutics Inc
NASDAQ:IPSC
Century Therapeutics Inc
Other Items
Century Therapeutics Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Century Therapeutics Inc
NASDAQ:IPSC
|
Other Items
$47.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.9B
|
CAGR 3-Years
-108%
|
CAGR 5-Years
31%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$1.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$691.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Century Therapeutics Inc
Glance View
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 170 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The firm's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.
See Also
What is Century Therapeutics Inc's Other Items?
Other Items
47.6m
USD
Based on the financial report for Dec 31, 2024, Century Therapeutics Inc's Other Items amounts to 47.6m USD.
What is Century Therapeutics Inc's Other Items growth rate?
Other Items CAGR 1Y
-36%
Over the last year, the Other Items growth was -36%.
